GH Research PLC
NASDAQ:GHRS
Overview | Financials
Company Name | GH Research PLC |
Symbol | GHRS |
Currency | USD |
Price | 6.85 |
Market Cap | 356,392,485 |
Dividend Yield | 0% |
52-week-range | 5.08 - 14.99 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Theis Terwey M.D. |
Website | https://www.ghres.com |
An error occurred while fetching data.
About GH Research PLC
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD